Format

Send to

Choose Destination
Anticancer Res. 2017 May;37(5):2593-2599.

Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.

Lu LC1,2,3, Chen PJ4,5,6, Yeh YC7, Hsu CH1,2, Chen HM2, Lai MS7, Shao YY8,2,3, Cheng AL1,2,5,3.

Author information

1
Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan, R.O.C.
2
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
3
National Taiwan University Cancer Center, Taipei, Taiwan, R.O.C.
4
Graduate Institutes of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
5
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
6
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
7
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, R.O.C.
8
Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan, R.O.C. yuyunshao@gmail.com.

Abstract

BACKGROUND:

Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC). We analyzed national prescription patterns and treatment outcomes of patients who received sorafenib for advanced HCC.

PATIENTS AND METHODS:

We established a nation-wide cohort of patients who started receiving treatment with sorafenib for advanced HCC between August 2012 and July 2013 from the National Health Insurance Research Database of Taiwan and also retrieved demographic and prescription data. The databases of National Death Registry and Taiwan Cancer Registry were used for survival outcomes and cancer diagnosis information, respectively.

RESULTS:

A total of 3,293 patients were enrolled. The median overall survival (OS) and time to treatment discontinuation (TTD) of all patients were 6.8 and 2.6 months, respectively. Upon the first prescription of sorafenib, 58.4% of patients received the standard dose (800 mg/day). Among them, 61.9% had subsequent dose reduction. A total of 41.6% of patients initially received lower than standard doses; 36.1% of them had subsequent dose escalation to 800 mg/day. Being male (odds ratio=1.41; p<0.001) and treatment year of 2012 (odds ratio=1.28; p=0.002) were associated with the standard initial dose. Patients who received standard initial dose of sorafenib, compared to patients who received lower initial doses, exhibited longer OS (median of 7.8 vs. 6.6 months, p<0.001) but similar TTD (median of 2.6 vs. 2.9 months, p=0.840).

CONCLUSION:

A considerable number of patients with advanced HCC received less than the standard dose of sorafenib. The treatment outcomes in the general population were consistent with those reported in clinical trials.

KEYWORDS:

Database research; dose; hepatocellular carcinoma; population study; prognosis; sorafenib

PMID:
28476832
DOI:
10.21873/anticanres.11604
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center